A collaborative approach to meeting oncology challenges in island communities in the Asia-Pacific region.

Treatment of cancer in small island communities is frequently challenged by the isolation and scattered nature of target populations, limited economic resources and overburdened healthcare systems. Strategies that have been successful in improving access to nonsurgical treatment in Fiji, Papua New Guinea, Solomon Islands and West Timor include balancing centralised location of scarce resources (particularly health professionals) with minimisation of patient travel, in-country training by teams of oncology professionals from high-income countries (HICs), sending health professionals to train in HICs, sharing and adaptation of treatment protocols, and telehealth initiatives. A common feature of successful initiatives is a collaborative approach.

Australia and New Zealand's responsibilities in improving oncology services in the Asia-Pacific: A call to action.

Aim: To review the expected increasing demand for cancer services among low and middle-income countries (LMICs) in the Asia-Pacific (APAC), and to describe ways in which Australia and New Zealand (ANZ) can provide support to improve cancer outcomes in our region.

Methods: We first review the current and projected incidence of cancer within the APAC between 2018 and 2040, and the estimated demand for chemotherapy, radiotherapy and surgery. We then explore potential ways in which ANZ can increase regional collaborations to improve cancer outcomes.

Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01).

Background: A short course of radiotherapy is commonly prescribed for palliative relief of malignant dysphagia in patients with incurable oesophageal cancer. We compared chemoradiotherapy with radiotherapy alone for dysphagia relief in the palliative setting.

Methods: This multicentre randomised controlled trial included patients with advanced or metastatic oesophageal cancer who were randomly assigned (1:1) through a computer-generated adaptive biased coin design to either palliative chemoradiotherapy or radiotherapy alone for treatment of malignant dysphagia at 22 hospitals in Australia, Canada, New Zealand, and the UK.

Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival.

Purpose: Three Phase II studies of preoperative radiotherapy and concurrent 5FU chemotherapy were undertaken. The primary endpoints were acute toxicity and pathologic complete response rate (pCR). Secondary endpoints were local recurrence-free survival (LRFS), disease-free survival (DFS), and overall survival (OS).